User talk:Robert.waldmann

conflict of interest ?
I am Robert Waldmann son of Thomas Waldmann. I tried to write an article sticking to citations of published sources. I hope this is OK.

Welcome!
Hello, Robert.waldmann, and welcome to Wikipedia!&#32;Thank you for your contributions.

I noticed that one of the first articles you edited was Thomas A Waldmann, which appears to be dealing with a topic with which you may have a conflict of interest. In other words, you may find it difficult to write about that topic in a neutral and objective way, because you are, work for, or represent, the subject of that article.&#32;Your recent contributions may have already been undone for this very reason.

To reduce the chances of your contributions being undone, you might like to draft your revised article before submission, and then ask me or another editor to proofread it. See our help page on userspace drafts for more details. If the page you created has already been deleted from Wikipedia, but you want to save the content from it to use for that draft, don't hesitate to ask anyone from this list and they will copy it to your user page.

One rule we do have in connection with conflicts of interest is that accounts used by more than one person will unfortunately be blocked from editing. Wikipedia generally does not allow editors to have usernames which imply that the account belongs to a company or corporation. If you have a username like this, you should request a change of username or create a new account. (A name that identifies the user as an individual within a given organization may be OK.)

In addition, if you receive, or expect to receive, compensation for any contribution you make, you must disclose your employer, client, and affiliation to comply with our terms of use and our policy on paid editing.

Here are some pages that you might find helpful:
 * Best practices for editors with close associations
 * Plain and simple conflict of interest guide
 * The five pillars of Wikipedia
 * Contributing to Wikipedia
 * Tutorial
 * How to edit a page and How to develop articles
 * How to create your first article (using the Article Wizard if you wish)
 * Simplified Manual of Style

I hope you enjoy editing here and being a Wikipedian! Please sign your messages on talk pages using four tildes ( ~ ); this will automatically insert your username and the date. If you need help, check out Questions, ask me on my talk page, or ask your question on this page and then place  before the question. Again, welcome! CommanderWaterford (talk) 13:36, 3 February 2021 (UTC)

Draft Article
Thomas A Waldmann (born 21 September 1930) is an American immunologist known for his work on therapeutic monoclonal antibodies to the IL-2 receptor, Interleukin 15 (IL-15), and Adult T-cell Leukemia (ATL). He is currently an active distinguished investigator at the Lymphoid Malignancies Branch of the National Cancer Institute.

Biography and career
Thomas Waldmann was born in New York City as the only child of Elisabeth Sipos and Charles Waldmann. He received his M.D. from Harvard Medical School in 1955. He joined the NCI in 1956 and became chief of the Lymphoid Malignancies Branch (formerly Metabolism Branch) in 1973. He married the late Katharine Waldmann in 1958 and has three Children: Richard, Robert, and Carol Waldmann.

Research
Waldmann's research has focused on lymphokines, their receptors, and use of lymphokines and monoclonal antibodies to their receptors in the treatment of cancer and of autoimmune diseases. He studied the IL-2/IL-2 receptor system in the growth of normal and neoplastic cells. He co-discovered IL-15 and has initiated clinical trials employing IL-15 in the treatment of metastatic malignancy.

He studied the role played by the receptor for interleukin-2 (IL-2) on the growth, differentiation and regulation of normal and neoplastic T-cells. He defined the IL-2 receptor subunits IL-2R beta and IL-2R alpha using the first reported anticytokine monoclonal antibody (anti-Tac) leading to the definition of the IL-2R alpha as a target for the therapy of leukemia and autoimmune diseases.

The scientific basis for this approach was the fact that normal resting cells do not express IL-2R alpha, but it is expressed by abnormal T-cells in patients with lymphoid malignancies. He introduced different forms of IL-2R-directed therapy, including unmodified murine antibodies to IL-2R alpha (anti-Tac, the first antibody to a cytokine receptor to receive FDA approval), humanized anti-Tac (daclizumab, Zenapax) and the antibody armed with toxins or alpha and beta-emitting radionuclides.

He showed that daclizumab contributes to reducing renal transplant rejection and is of value in the treatment of T-cell-mediated autoimmune disorders including multiple sclerosis.

He demonstrated that refractory and relapsed Hodgkin's lymphoma (HL) patients could be effectively treated with daclizumab armed with Yttrium-90, because most normal cells do not express CD25, but it is expressed by some Reed-Sternberg cells and by rosetting polyclonal T-cells in lymphomatous masses. Responses were seen among the patients whose Reed-Sternberg cells were CD25 negative, provided that the associated rosetting T-cells expressed CD25.

Waldmann co-discovered the cytokine interleukin 15 (IL-15) and elucidated its role in the development of NK and CD8-memory T cells and its inhibition of activation induced cell death. He demonstrated that it is bound to IL-15 R alpha on the surface of antigen presenting cells and presented in trans to T-cells in an immune synapse He demonstrated that IL-15 is useful in the treatment of cancer in mice and has completed a clinical trial using IL-15 in therapy of patients with metastatic malignant melanoma and renal cell cancer.

Furthermore, Waldmann demonstrated that vaccines containing IL-15 induced long-lasting, high-avidity CD8-mediated CTL immunity.

Waldmann studied adult T-cell leukemia that develops in individuals infected with the retrovirus human T-cell lymphotropic virus-1 (HTLV-1). Dr. Waldmann demonstrated that the HTLV-1 encoded protein Tax constitutively activates two autocrine (IL-2R/IL-2, IL-15R/IL-15) and one paracrine (IL-9) system. Waldmann demonstrated that daclizumab provides effective therapy for some patients with a previously invariably fatal leukemia, HTLV-I associated adult T-cell leukemia (ATL).

In the early 80s Waldmann studied immunoglobulin gene rearrangement in and cell surface markers on acute lymphocyte leukemias

In 1961 Waldmann described Waldmann disease.

Honorary Societies

 * National Academy of Sciences,
 * American Academy of Arts and Sciences,
 * National Academy of Medicine,
 * Fellow National Academy of Inventors,
 * Association of American Physicians
 * American Society for Clinical Investigation
 * Honorary Fellow, American Academy of Allergy and Immunology
 * The Hungarian Academy of Sciences
 * Fellow American Association for the Advancement of Sciences
 * Honorary Life Membership Clinical Immunology Society
 * Fellow American Academy of Microbiology
 * Honorary Life Membership of the International Cytokine Society
 * Honorary Fellow Royal Society of the Medical Sciences (UK)
 * Election to the Henry Kunkle Society
 * Fellow American Physiological Society
 * Honorary Member Clinical Immunology Society

Awards
1986	Lila Gruber Cancer Research Award, American Academy of Dermatology, 1987	Ciba-Geigy Drew Award in Biomedical Research, 1987	Simon Shubitz Prize for Cancer Research, University of Chicago Medical School, 1989	Milken Family Medical Foundation, Distinguished Basic Scientist Award, 1990	Doctor Honoris Causa, University Medical School, Debrecen, Hungary, 1991	Artois-Baillet Latour Health Prize, 1992	15th Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research, 1996	Paul Ehrlich Medal, Paul Ehrlich Institute, 1998   American College of Physicans Award for Distinguished Contributions to Science as Related to Medicine, 2002	American Academy of Microbiology-Abbott Laboratories Prize in Clinical Diagnostic Immunology, 2005   Debrecen Prize in Molecular Medicine, 2007	AAI- Ralph Steinman Award for Human Immunology Research, 2009	Service to America (SAMMIE) Career Achievement Medal, 2011   Establishment of the Annual Thomas Waldmann Award Foundation for Primary Immunodeficiency Diseases (FPID), 2011	Establishment of the Tom Waldmann Lecture, Jeffrey Modell World Immunology Conference, 2012	Institute of Human Virology Life-time Achievement Award, 2012	FLC Award for Excellence in Technology Transfer for use of Therapeutic Antibodies as a Novel Treatment for Multiple Sclerosis, 2018	Albert Nelson Marquis Lifetime Achievement Award, 1980   Man of the Year Award of American Leukemia Society (New York), 1990   Honor Award for Original Contribution to Human Retrovirology HTLV-I Society, 1990   Jeffrey Modell Foundation Lifetime Achievement Award, 1991   Landmarks in Allergy and Clinical Immunology Award in Clinical Immunology, 1991   4th Annual Duke University Award for Excellence in Immunologic Research, 1998   Governor's Award, Washington, D.C., American College of Physicians, 2003   3rd Time Gee Award Sass Foundation, 2007   President's Award Clinical Immunology Society,

Speedy deletion nomination of User:Robert.waldmann/Thomas


A tag has been placed on User:Robert.waldmann/Thomas requesting that it be speedily deleted from Wikipedia. This has been done for the following reason:

"User accidentally posted article draft on his user page, asked me now for help"

Under the criteria for speedy deletion, pages that meet certain criteria may be deleted at any time.

If you think this page should not be deleted for this reason, you may contest the nomination by visiting the page and clicking the button labelled "Contest this speedy deletion". This will give you the opportunity to explain why you believe the page should not be deleted. However, be aware that once a page is tagged for speedy deletion, it may be deleted without delay. Please do not remove the speedy deletion tag from the page yourself, but do not hesitate to add information in line with Wikipedia's policies and guidelines. If the page is deleted, and you wish to retrieve the deleted material for future reference or improvement, then please contact the, or if you have already done so, you can place a request here. CommanderWaterford (talk) 18:12, 3 February 2021 (UTC)